Stockscreener 앱 받기
4.8072
15.79%
-0.8928
전일 마감가:
$5.70
열려 있는:
$5.49
하루 거래량:
28.27M
Relative Volume:
1.18
시가총액:
$2.37B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.1014
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-17.81%
1개월 성능:
+13.21%
6개월 성능:
-29.62%
1년 성능:
-45.70%
1일 변동 폭
$4.76
$5.80
1주일 범위
$4.76
$5.94
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.805 | 2.37B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.11 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.32 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.46 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.26 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Strategic Focus - GuruFocus
Recursion Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
AI specialist Recursion trims pipeline in latest shakeup - BioPharma Dive
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com India
Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down - Nasdaq
Document - SEC.gov
Recursion Pharmaceuticals earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases - marketscreener.com
Recursion Pharmaceuticals: Q1 Earnings Snapshot - San Francisco Chronicle
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial - marketscreener.com
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings (NASDAQ:RXRX) - Seeking Alpha
Recursion (RXRX) Reports Promising Results for FAP Treatment - GuruFocus
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | RXRX Stock News - GuruFocus
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - GlobeNewswire Inc.
Recursion Pharmaceuticals (RXRX) Set to Release Q1 Earnings - GuruFocus
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - MSN
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - Bluefield Daily Telegraph
TechBio Pioneer Recursion Announces Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Recursion (RXRX) to Reveal Promising Data on REC-4881 for FAP Tr - GuruFocus
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know - MSN
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - marketscreener.com
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - marketscreener.com
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - Insider Monkey
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? - MSN
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):